Harry Wagner v. First Horizon Pharmaceutical Corp.

464 F.3d 1273, 2006 U.S. App. LEXIS 23690
CourtCourt of Appeals for the Eleventh Circuit
DecidedSeptember 18, 2006
Docket05-14365
StatusPublished
Cited by245 cases

This text of 464 F.3d 1273 (Harry Wagner v. First Horizon Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Harry Wagner v. First Horizon Pharmaceutical Corp., 464 F.3d 1273, 2006 U.S. App. LEXIS 23690 (11th Cir. 2006).

Opinion

BIRCH, Circuit Judge:

In this appeal, we determine that even securities claims without a fraud element must be pled with particularity pursuant to Federal Rule of Civil Procedure 9(b); when that nonfraud securities claim is alleged to be part of a defendant’s fraudulent conduct. We also remind district courts of their supervisory obligation to sua sponte order repleading pursuant to Federal Rule of Civil Procedure 12(e) when a shotgun complaint fails to link adequately a cause of action to its factual predicates. Applying these determinations to this case, we VACATE the district court’s orders and REMAND WITH INSTRUCTIONS to order repleading.

I. BACKGROUND

This securities class action alleges violations of both the Securities Act of 1933 (“Securities Act”), 15 U.S.C. § 77a, et seq., and the Securities Exchange Act of 1934 (“Exchange Act”), 15 U.S.C. § 78a, et seq. Because the case is before us on a motion to dismiss, we draw all inferences in favor of the plaintiffs. See Bryant v. Avado Brands, Inc., 187 F.3d 1271, 1273 n. 1 (11th Cir.1999). The class of plaintiffs in this case consists of all people who traded First Horizon securities between 24 April 2002 and 29 April 2003. A subclass of these plaintiffs consists of those people who purchased common stock in First Horizon’s secondary offering and relied on a 5 March 2003 Registration Statement, which subsequently was amended.

First Horizon is a pharmaceutical company that markets and sells, but does not develop, prescription drugs. First Horizon focuses its marketing efforts on the physicians who prescribe the drugs but *1276 sells the drugs only to wholesalers, drug store chains, retail merchandisers, and, occasionally, directly to retail pharmacies. Plaintiffs allege that there is a disconnect between First Horizon’s marketing efforts and its sales such that reports of increased prescriptions by physicians may not reflect accurately increased sales from First Horizon to its distributors and retailers.

The secondary offering that underpins the Securities Act claim was completed to finance the acquisition of a new product line, Sular, which is an anti-hypertension drug. Plaintiffs contend that First Horizon needed to maintain market confidence in its securities in order to keep the trading price of its stock at a price that would bring in enough capital for the number of shares First Horizon desired to add to the market. Plaintiffs allege that First Horizon, therefore, employed a fraudulent scheme to control the revenue growth. The gist of the fraudulent scheme was to push more inventory into the supply chain and to recognize revenue without increased market demand for the product, that is, without increased sales by the product’s distributors and retailers.

Reviewing defendants’ motions to dismiss, the district court concluded that the plaintiffs had “fail[ed] to link their specific allegata to the causes of action pled in their complaint” and that this failure meant that plaintiffs had not met the pleading requirements of Rule 9(b) and the Private Securities Litigation Reform Act, 15 U.S.C. § 78u-4(b) (“PSLRA”). R6-68 at 36. Anticipating a motion to amend, the court conditioned any such amendment on the payment of defendants’ costs and fees associated with the motion to dismiss.

Plaintiffs filed a motion to lift that condition. The district court denied that motion and observed that both parties had “defaulted” on the “court’s offer.” R6-77 at 7. The court then “extend[ed] substantially the' same offer”: defendants were to submit a claim for fees and costs with information sufficient to allow the court to determine their reasonableness, and plaintiffs were to file an amended complaint “with the understanding that Plaintiffs will have to pay some reasonable fee for the Defendants’ fees and costs associated with the motions to dismiss.” Id. at 7-8. The court noted that the plaintiffs then could reargue the reasonableness of the defendants’ requested expenses and whether the court should impose them at all.

Plaintiffs allowed the conditional period to expire and filed a notice of appeal challenging both orders. 1 On appeal, plaintiffs continue to argue the merits of whether the complaint stated a claim and whether the district court properly conditioned amendment of the complaint. As discussed in the subsequent section, we strike a different path and conclude that the complaint is so deficient that the court sua sponte should have ordered replead-ing.

II. DISCUSSION

We review de novo a district court order granting a motion to dismiss. Oxford As *1277 set Mgmt., Ltd. v. Jaharis, 297 F.3d 1182, 1187 (11th Cir.2002). First, we determine when nonfraud claims under the Securities Act must be pled with particularity. Second, we review the district court’s conclusions about whether the plaintiffs met their heightened pleading burden.

A. When Nonfraud Claims Must Be Pled with Particularity

Section 11 of the Securities Act creates a cause of action against persons preparing and signing materially misleading registration statements. 15 U.S.C. § 77k(a). A registration statement can be misleading either by containing an untrue statement or by omitting facts that are necessary to prevent other statements from being misleading. Id. There is no state of mind element to a § 11 claim, and liability is “virtually absolute, even for innocent misstatements.” Herman & Mac-Lean v. Huddleston, 459 U.S. 375, 382, 103 S.Ct. 683, 687, 74 L.Ed.2d 548 (1983). Likewise, § 12(a)(2) extends similar liability to misrepresentations in prospectuses and oral communications. See 15 U.S.C. § 771(a)(2). It is clear that neither allegations of fraud nor scienter are necessarily part of either of these claims. For this reason, we refer to these two claims as “nonfraud” claims in this opinion.

The question presented to us, however, regards whether there are circumstances when Federal Rule of Civil Procedure 9(b) would require nonfraud securities claims to be pled with particularity.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
464 F.3d 1273, 2006 U.S. App. LEXIS 23690, Counsel Stack Legal Research, https://law.counselstack.com/opinion/harry-wagner-v-first-horizon-pharmaceutical-corp-ca11-2006.